stoxline Quote Chart Rank Option Currency Glossary
  
Kinnate Biopharma Inc. (KNTE)
2.68  0.02 (0.75%)    03-28 11:27
Open: 2.66
High: 2.69
Volume: 40,084
  
Pre. Close: 2.66
Low: 2.66
Market Cap: 126(M)
Technical analysis
2024-03-28 10:47:49 AM
Short term     
Mid term     
Targets 6-month :  3.14 1-year :  3.66
Resists First :  2.69 Second :  3.14
Pivot price 2.59
Supports First :  2.53 Second :  2.44
MAs MA(5) :  2.65 MA(20) :  2.59
MA(100) :  2.32 MA(250) :  2.63
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  85.9 D(3) :  81.4
RSI RSI(14): 67.2
52-week High :  7.18 Low :  1.03
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ KNTE ] has closed below upper band by 8.0%. Bollinger Bands are 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.68 - 2.69 2.69 - 2.71
Low: 2.6 - 2.62 2.62 - 2.64
Close: 2.63 - 2.66 2.66 - 2.69
Company Description

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Headline News

Thu, 28 Mar 2024
Kinnate Biopharma Inc. (NASDAQ:KNTE) Short Interest Down 43.6% in March - MarketBeat

Mon, 25 Mar 2024
2024-03-25 | NDAQ:KNTE | Press Release | Kinnate Biopharma Inc - Stockhouse Publishing

Fri, 22 Mar 2024
Citigroup Inc. Purchases 419,795 Shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) - MarketBeat

Fri, 22 Mar 2024
Citigroup Inc. Buys 419795 Shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) - Defense World

Wed, 13 Mar 2024
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... - Business Wire

Fri, 01 Mar 2024
Kinnate Biopharma Strikes Major Deal on Drug Rights - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 47 (M)
Shares Float 23 (M)
Held by Insiders 0.1 (%)
Held by Institutions 82.5 (%)
Shares Short 825 (K)
Shares Short P.Month 1,100 (K)
Stock Financials
EPS -2.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.66
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -33.7 %
Return on Equity (ttm) -55.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.8
Qtrly Earnings Growth 0 %
Operating Cash Flow -106 (M)
Levered Free Cash Flow -60 (M)
Stock Valuations
PE Ratio -0.97
PEG Ratio 0
Price to Book value 0.73
Price to Sales 0
Price to Cash Flow -1.2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android